We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Oxford Gene Technology Joins Chavi Funded Project to Provide Microarrays for HIV Vaccine Research

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Oxford Gene Technology (OGT) has announced that it has been selected to design and fabricate microarrays for the Innate Discovery Team as part of the Centre for HIV-AIDS Vaccine Immunology research project to develop vaccines for HIV.

The team is led by Professor Andrew McMichael, senior scientific leader, Oxford University and Dr Persephone Borrow of the Edward Jenner Institute.     

OGT will design and develop an optimised oligonucleotide microarray to study genes of interest involved in the cellular immune response in early stage HIV infected patients.

The microarrays will be printed using the OGT ink jet in-situ synthesis (IJISS) platform and will investigate the use of its Multi Sample Array (MSA) format enabling the parallel analysis of multiple samples.

Mr James Clough, Commercial Director at OGT said: “We are very excited to be working with Professor McMichael’s team and the wider CHAVI network. OGT’s complete microarray solution combines its bioinformatics expertise with innovative microarray technology and is well suited to the project task.”